Eric Green

When a nurse draws medicine from a vial, the rubber stopper was likely made by West. When a patient self-injects a biologic therapy using a prefilled syringe or autoinjector, the elastomeric components and often the device itself were made by West. West's products are classified as primary packaging — components that directly contact the drug and are therefore subject to rigorous pharmaceutical regulatory requirements. Changing a primary packaging component requires expensive and time-consuming regulatory filings, creating enormous switching costs. Once a drug is approved with West components, they are essentially locked in for the product's commercial life. The biologics revolution has been a powerful tailwind: biologic drugs (antibodies, cell therapies, gene therapies) are more sensitive than traditional small molecules and require higher-quality containment — premium West products like NovaPure and Flurotec-coated components. Key stock drivers include injectable drug market growth, biologics development pipeline, COVID vaccine booster demand normalization, Proprietary Products segment margins, high-value product adoption, customer inventory destocking cycles, competition with Datwyler and Aptar Pharma, and the overall trajectory of injectable drug administration.